Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melanoma addiction to the long non-coding RNA SAMMSON.
Leucci E, Vendramin R, Spinazzi M, Laurette P, Fiers M, Wouters J, Radaelli E, Eyckerman S, Leonelli C, Vanderheyden K, Rogiers A, Hermans E, Baatsen P, Aerts S, Amant F, Van Aelst S, van den Oord J, de Strooper B, Davidson I, Lafontaine DL, Gevaert K, Vandesompele J, Mestdagh P, Marine JC. Leucci E, et al. Among authors: rogiers a. Nature. 2016 Mar 24;531(7595):518-22. doi: 10.1038/nature17161. Nature. 2016. PMID: 27008969
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Talebi A, Dehairs J, Rambow F, Rogiers A, Nittner D, Derua R, Vanderhoydonc F, Duarte JAG, Bosisio F, Van den Eynde K, Nys K, Pérez MV, Agostinis P, Waelkens E, Van den Oord J, Fendt SM, Marine JC, Swinnen JV. Talebi A, et al. Among authors: rogiers a. Nat Commun. 2018 Jun 27;9(1):2500. doi: 10.1038/s41467-018-04664-0. Nat Commun. 2018. PMID: 29950559 Free PMC article.
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, Levesque M, Piris A, Frederick DT, Boland G, Flaherty KT, van den Oord J, Voet T, Aerts S, Lund AW, Marine JC. Rambow F, et al. Among authors: rogiers a. Cell. 2018 Aug 9;174(4):843-855.e19. doi: 10.1016/j.cell.2018.06.025. Epub 2018 Jul 12. Cell. 2018. PMID: 30017245 Free article.
Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A, Thomas D, Vander Borght S, van den Oord JJ, Bechter O, Dewaele M, Rambow F, Marine JC, Wolter P. Rogiers A, et al. Br J Dermatol. 2019 Feb;180(2):421-422. doi: 10.1111/bjd.17250. Epub 2018 Nov 22. Br J Dermatol. 2019. PMID: 30248172 No abstract available.
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.
Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, Bervoets G, Van Raemdonck N, Pedri D, Swings T, Demeulemeester J, Borght SV, Lehnert S, Bosisio F, van den Oord JJ, Bempt IV, Lambrechts D, Voet T, Bechter O, Rizos H, Levesque MP, Leucci E, Lund AW, Rambow F, Marine JC. Marin-Bejar O, et al. Among authors: rogiers a. Cancer Cell. 2021 Aug 9;39(8):1135-1149.e8. doi: 10.1016/j.ccell.2021.05.015. Epub 2021 Jun 17. Cancer Cell. 2021. PMID: 34143978 Free article.
Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy.
Talebi A, de Laat V, Spotbeen X, Dehairs J, Rambow F, Rogiers A, Vanderhoydonc F, Rizotto L, Planque M, Doglioni G, Motamedi S, Nittner D, Roskams T, Agostinis P, Bechter O, Boecxstaens V, Garmyn M, O'Farrell M, Wagman A, Kemble G, Leucci E, Fendt SM, Marine JC, Swinnen JV. Talebi A, et al. Among authors: rogiers a. J Exp Clin Cancer Res. 2023 Apr 19;42(1):92. doi: 10.1186/s13046-023-02664-7. J Exp Clin Cancer Res. 2023. PMID: 37072838 Free PMC article.
51 results